Zambon entered in an exclusive license agreement to register and commercialize riluzole Oral Film in Europe for ALS
Warren, NJ, November 13, 2019 – Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that it granted a license to Zambon S.p.A. for the development and commercialization of Riluzole Oral Film (ROF) in the European Union for the treatment of amyotrophic lateral sclerosis (ALS). Zambon is a multinational pharmaceutical company strongly committed to innovating cure and care to make patients’ lives better, with a focus on the central nervous system (CNS) therapeutic area.
“We are proud to announce that Zambon will register and commercialize in the European Union Riluzole Oral Film. Thanks to this collaboration with Aquestive, Zambon will further strengthen its commitment to orphan diseases and to the CNS area, enriching its portfolio with a new formulation that will concretely help patients. Zambon is committed to improve people’s quality of life through innovative medicines and modern therapeutic solutions where they are mostly needed,” said Roberto Tascione, CEO of Zambon S.p.A.